Petros Pharmaceuticals $PTPI Read from its own SEC filings · nothing written, nothing inferred
🫧 Edgar looked up Petros Pharmaceuticals, Inc. ($PTPI). Last filing: 8-K (1.03 Bankruptcy or Receivership), 2026-09-30. 5 event filings (8-K) in the past twelve months. Auditor change (8-K Item 4.01) filed 2025-09-05.
🔖 Exposure: revenue $5.1M (FY2024). Experience: revenue down 12.2% on the year, down 14.5% a year over 4 years; operating margin -90.5%, up from -233.9%. Soundness: equity -70.2% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $2.8M and $6.8M next year (method v4.1: its own 4-year record of growth weighed at 50% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $2.7M to $7.2M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -90.5% against a -3.8% median; growth -12.2% against 13.7%.
Speed and cash · fiscal 2024
Both views must agree for a label · a description, not advice.
| Cash flow (op · inv · fin · free) | −$3M · −$0M · −$7M · −$3M |
| Investment book (cash · short · long) | $2M · — · — · current ratio 0.40 |
| Revenue swing · equity of assets | 10.2% · -70.2% |
Petros Pharmaceuticals is growing slower than its size class, with steadier revenue. Its own audited SEC figures.
The figures, as filed
| Fiscal year end | 2024-12-31 |
| Revenue | $5M |
| Revenue, on the year | −12.2% |
| Revenue, a year over the record | −14.5% |
| Operating margin | −90.5% |
| Operating margin, prior year | −233.9% |
| Net margin | −280.1% |
| Research and development | $3M · 51.2% of revenue |
| Total debt | — |
| Equity of assets | −70.2% |
| Return on equity | — |
| Payout of profit | — |
| Dividend per share | — |
| Earnings per share | $-83.47 |
| Book value per share | $-23.26 |
| Revenue per share | $15.92 |
| Shares outstanding | 321,042 |
| Audited years read | 5 |
Peers: the median of 114 filers with $50M+ revenue in pharmaceutical preparations.
Health HarborPetros Pharmaceuticals sails as: Rotting at the dock
Health watch · 12 monthsBankruptcy or receivershipLate annual report noticeExchange listing notice or transferDebt accelerated or triggeredDirector or officer change ×4
Tied up at the dock.
🌊 Visit the Bay →- filed bankruptcy or receivership, late annual report notice, debt accelerated or triggered in the last 12 months
- liabilities exceed assets (often from years of share buybacks, not always distress)
- operating cash flow was negative
- revenue is hard to predict: its 80% range is ±41%
Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.
- 8-K · 2026-09-30 · 1.03 Bankruptcy or Receivership; 2.04 Triggering Events That Accelerate a Financial Obligation; 5.02 Departure or Election of Directors; Appointment of Officers
- 10-Q · 2026-08-13
- 8-K · 2026-06-18 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits
- 8-K · 2026-06-05 · 5.02 Departure or Election of Directors; Appointment of Officers
- 10-Q · 2026-05-13
- 10-K · 2026-04-15
Its latest audited year is FY2025, which reports no revenue; the revenue figures and the range here are from FY2024, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · ask about another company